Gilead Sciences, Inc. (NASDAQ:GILD) on June 15 announced topline results from a Phase 3 clinical trial (GS-US-337-0113) in Japan evaluating the investigational once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 1.80% in last session and finished the day at $88.68. Traded volume was 10.40million shares in the last session and the average volume of the stock remained 14.02million shares. The beta of the stock remained 0.71. Gilead Sciences, Inc. (NASDAQ:GILD) insider ownership is 0.50%.

Baxter International Inc. (NYSE:BAX) said Wednesday it has acquired AesRx LLC, a small Massachusetts-based pharmaceutical firm focused on orphan drug treatments, for an undisclosed amount.Baxter International Inc. (NYSE:BAX) rose 0.58 percent to $75.82 Wednesday on volume of 2.52million shares. The intra-day range of the stock was $75.14 to $76.05. Baxter International Inc. (NYSE:BAX) has a market capitalization of $41.14billion.

WellPoint Inc. (NYSE:WLP) has called Sovaldi its “biggest watch item,” budgeting $100 million of additional hepatitis C drug costs to its 2014 outlook after spending close to $50 million on it during the first quarter. WellPoint Inc (NYSE:WLP)’s stock on July 09, 2014 reported a increase of 1.29% to the closing price of $110.87. Its fifty two weeks range is $81.46 -$111.08. The total market capitalization recorded $31.01billion. The overall volume in the last trading session was 2.08million shares. In its share capital, WLP has 279.67million outstanding shares.

The Cooper Companies (NYSE:COO) CEO Robert S. Weiss sold 121,200 shares of the company’s stock on the open market in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of $145.03, for a total value of $17,577,636.00. Following the completion of the sale, the chief executive officer now directly owns 80,500 shares in the company, valued at approximately $11,674,915On Wednesday, shares of The Cooper Companies, Inc. (NYSE:COO) advanced 2.95% to close the day at $149.54. Company return on investment (ROI) is 10.60% and its monthly performance is recorded as 12.28%. The Cooper Companies, Inc. (NYSE:COO) quarterly revenue growth is 14.65%.

iKang Healthcare Group, Inc. (“iKang” or the “Company”) (NASDAQ:KANG), the largest provider in China’s fast growing private preventive healthcare services market in terms of revenue in 2013, on 30 June 2014 announced that it has completed 100% acquisition of Shanghai Huajian Clinic Ltd. (“Huajian”), a well-known middle-to-high end brand in Shanghai’s medical examination market. iKang first acquired a 33% equity in Huajian in January 2014, which has been disclosed in iKang’s prospectus for its initial public offering, and subsequently acquired the remaining 67% equity in Huajian. iKang Healthcare Group Inc (ADR) (NASDAQ:KANG) stock performance was 4.98% in last session and finished the day at $19.80. Traded volume was 459,272.00million shares in the last session and the average volume of the stock remained 443.36K shares.